Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective
This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246...
Source: J Pharm Pharm Sci - October 30, 2023 Category: Drugs & Pharmacology Authors: Allison Wills Arif Mitha Winson Y Cheung Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
Clinical observation of dexmedetomidine nasal spray in the treatment of sleep disorders on the first night after undergoing maxillofacial surgery: a single-center double-blind randomized controlled study
Conclusion: The sleep quality of participants on the night after having undergone maxillofacial surgery was safely and effectively improved by 1.0-1.5 μg/kg dexmedetomidine atomized nasal sprays. Notably, only the latter could prolong N3 sleep. Level of Evidence II: Evidence was obtained from at least one properly designed randomized controlled trial.PMID:37854323 | PMC:PMC10579589 | DOI:10.3389/jpps.2023.11699 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - October 19, 2023 Category: Drugs & Pharmacology Authors: Ye Wang Zibin Jin Wenli Xu Keyu Chen Lingxin Wei Dong Yang Xiaoming Deng Shiyi Tong Source Type: research
